Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Primary Generalized Tonic-Clonic Seizures
Interventions: XEN1101, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 62
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bipolar Disorder, Insulin Resistance
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Interventions: Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose], Glucocorticoids [Reduced Dose]; Procedure · Other · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 9
States / cities: Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Prostate Cancer
Interventions: Apalutamide, Placebo, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 39
States / cities: Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more

Conditions: Non-Small Cell Lung Cancer
Interventions: ASA404, Placebo, carboplatin, Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 100
States / cities: Mobile, Alabama • Tucson, Arizona • Bentonville, Arkansas + 86 more

Conditions: Post Operative Pain
Interventions: SABER-Bupivacaine (Part 1), SABER-Bupivacaine (Part 2), Saline Placebo, Bupivacaine HCl; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 21
States / cities: Florence, Alabama • Sheffield, Alabama • Arcadia, California + 13 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 114
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more

Conditions: End Stage Renal Disease
Interventions: massage; Other
Lead sponsor: Catherine Sullivan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetic Macular Edema (DME)
Interventions: 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 59
States / cities: Scottsdale, Arizona • Encino, California • Fullerton, California + 52 more

Conditions: Lymphangioleiomyomatosis
Interventions: Sirolimus, Everolimus; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 20
States / cities: Stanford, California • Denver, Colorado • Jacksonville, Florida + 17 more

Conditions: Kidney Stone
Interventions: vacuum assisted sheath, passive suction via conventional sheath; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cervical Ripening, Induction of Labor
Interventions: weighted bag, leg taping; Other
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions: Larotrectinib Sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 78
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more

Conditions: Volume Overload
Interventions: Oral Sodium Chloride, Placebo; Dietary Supplement · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: Chloroquine, Placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more

Conditions: Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Interventions: ADX-324, Placebo; Drug
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Litchfield Park, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 16 more

Conditions: Lung Diseases, Interstitial
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: Epilepsy
Interventions: self-management; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vertebral Artery Stenosis
Interventions: Observational Prospective Registry; Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: Jacksonville, Florida • Tampa, Florida • Winfield, Illinois + 7 more

Conditions: Pulmonary Embolism, Pulmonary Thromboembolism
Interventions: Catheter-Directed Thrombolysis, FlowTriever System; Device
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Loma Linda, California • Orange, California • Pasadena, California + 46 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 58
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more

Conditions: Parkinson Disease, Constipation
Interventions: Active Investigational Treatment ENT-01; Drug
Lead sponsor: Enterin Inc.; Industry
Eligibility: 30 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Fountain Valley, California • Pasadena, California • Englewood, Colorado + 15 more

Conditions: Respiratory Insufficiency, Anoxemia
Interventions: Nitrogen gas, inhaled nitric oxide; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: Up to 16 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 16
States / cities: Orange, California • Stanford, California • Denver, Colorado + 13 more

Search by objective public record fields.

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

Pioglitazone for the Treatment of Bipolar Depression

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Trial of Extended Release Bupivacaine for Pain Relief After Surgery

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

Safety and Durability of Sirolimus for Treatment of LAM

Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis

Foley Bulb Traction for Cervical Ripening

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Self-management for People With Epilepsy and a History of Negative Health Events

Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)

The PEERLESS Study

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover)

Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics